Reviews/Polyphenols and Antioxidants/Polyphenol bioavailability is low
Bio · POLY-BIO-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across the corpus, individual polyphenols were measured one compound at a time in small human crossover trials, and the picture that emerges is uneven rather than uniform. Some compounds appear in blood at very low levels, such as wild blueberry anthocyanins and chlorogenic acid [13], while cocoa flavanols are only moderately absorbed [7] and unformulated fisetin [1] and curcumin [5] are described as poorly available. At the same time, several studies show that a range of polyphenols are measurably absorbed [9][11][12], and absorption shifts with food processing, fat and the surrounding matrix [2][6] as well as between people [8]. One cocoa study even found that the amount reaching the blood was reproducible within the same person over time [10]. The panel landed on a supported-but-qualified position because the direction holds while no study measures polyphenols as a whole class or sets a numerical threshold for what counts as low, and genuine counter-examples remain.
The corpus demonstrates low systemic availability for specific compounds, most sharply in [13], which reports anthocyanin and 3-chlorogenic-acid bioavailability of 1.1% and 0.2%, and in [7], where cocoa flavanols are called moderately bioavailable with a 35% recovery. Unformulated fisetin [1] and curcumin [5] are framed as limited by poor or low oral bioavailability, and betanin was undetectable in plasma [14]. Variability is shown by processing and fat raising tomato polyphenol absorption [2], juice versus smoothie differing for 3,4-dihydroxybenzoic acid [6], and substantial interindividual differences in [8]. Against this, [12] concludes a number of polyphenols are bioavailable, [11] calls them readily available in circulation, and [9] shows significant plasma increases, while [10] reports high intra-individual correlation (r=0.72). The contested point: The division is whether 'low' describes the polyphenol class or only certain hydrophobic compounds and anthocyanins, given that [9], [11] and [12] show adequate absorption for others. A second point of division is whether 'highly variable' is demonstrated or merely assembled, since [10] shows within-person reproducibility and the spread is largely between compounds and matrices rather than chaotic within-subject.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No corpus paper measures polyphenol bioavailability as a class or defines 'low' against a threshold; the claim is a textbook generalisation and the corpus is a set of single-compound PK studies, so 'highly variable' is almost tautologically true of the assembled heterogeneity rather than demonstrated.
Direct counter-evidence to 'low': [12] states polyphenols are bioavailable, [11] calls them 'readily available in circulation', and [9] shows significant plasma increases — 'low' holds mainly for hydrophobic compounds (curcumin, fisetin) and anthocyanins, not the class.
Where it remains uncertain. Several polyphenols are reported as measurably bioavailable [9][11][12] and one study shows strong within-person reproducibility [10], so 'low and highly variable' is compound-dependent rather than a measured class property.
Aleatory
Substantial person-to-person differences in response [8], reflecting genuine biological spread rather than measurement error
Epistemic
No paper measures polyphenol bioavailability as a class; the corpus is single-compound PK studies [1][5][7][13]
Inferential
Inferring a class property from heterogeneous single-compound studies risks anecdote-stacking rather than estimation
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
States poor oral bioavailability as the limiting property of an unformulated polyphenol.
“the clinical effectiveness of fisetin may be limited by its poor bioavailability when ingested”
Panel auditInternal validity: medium · scope of inference: Single-dose oral fisetin in healthy adults; speaks only to this one polyphenol.Key limitations: one polyphenol only · poor bioavailability stated as premise · small n · formulation-development study
Demonstrates bioavailability varies with food processing and matrix — supports 'highly variable'.
“Processing tomatoes into sauce enhanced the bioavailability of flavanones, flavanols, and some hydroxycinnamic acids, as reflected by the increase in the area under the plasma concentration versus time curve.”
Panel auditInternal validity: medium · scope of inference: Bioavailability of tomato flavanones, flavanols and hydroxycinnamic acids as affected by processing and fat.Key limitations: no absolute bioavailability reported · no variability metric · matrix-effect framing not low-vs-high
Supports 'low' for curcumin (non-human PK; included at relevance 3).
“the application of curcumin for animal production and human life is limited by a low oral bioavailability”
Panel auditInternal validity: medium · scope of inference: Oral curcumin bioavailability in beagle dogs; one polyphenol.Key limitations: animal model · one polyphenol · low BA stated as premise · no interindividual variability reported
Plasma polyphenols/flavonoids rose significantly after pigmented rice, demonstrating absorption occurs, but nothing in the abstract quantifies whether bioavailability is low or variable.
Panel auditInternal validity: medium · scope of inference: Acute plasma polyphenol/flavonoid rise after pigmented rice in healthy subjects.Key limitations: no absolute BA fraction · no variability metric · total plasma polyphenols not individual kinetics
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus consistently carries the direction of 'low and variable' through accumulated single-compound evidence, but heterogeneity, absence of a class-level measure, and genuine counter-examples cap confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No class-level bioavailability measure. Every paper measures one compound, so the corpus cannot say whether 'low' describes polyphenols as a class or only subsets The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A standardised multi-compound human study reporting absolute bioavailability across polyphenol classes on a common scale
Open question: Is oral bioavailability low across polyphenol classes, or confined to hydrophobic compounds and anthocyanins? Why it is still open: Low figures appear for anthocyanins and chlorogenic acid [13], fisetin [1] and curcumin [5], yet [9][11][12] report adequate absorption of other polyphenols
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19